Qian Fenglei Takes the Helm at WellCell Group, Reshaping the Business Landscape

---
Qian Fenglei Takes the Helm at WellCell Group, Reshaping the Business Landscape
Vote:
0 0
Previous China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC
Next SANY Delivers the First Hydrogen Refueling Project to Australia, Marking a Milestone in Global Green Energy Expansion

Related News

Qian Fenglei Restructures Capital Market with "FO-X" Strategy: Acquires 600 Million HKD Stake to Take Control of WellCell, Aiming for Trillion-Dollar Web3 Ecosystem

Inaugural Asia FII PRIORITY Summit Powered By FII Institute To Take Place In Hong Kong On 7 & 8 December

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

menu
menu